Business Description
Takeda Pharmaceutical Co Ltd
NAICS : 325412
SIC : 2834
ISIN : US8740602052
Compare
Compare
Traded in other countries / regions
TKD.AustriaTAKP34.BrazilTKD.Germany4502.JapanTAK.Mexico4502.Switzerland0RN3.UKTKPHF.USA IPO Date
2010-05-11Description
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.13 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.69 | |||||
| Debt-to-EBITDA | 3.45 | |||||
| Interest Coverage | 2.11 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 1.13 | |||||
| Beneish M-Score | -2.72 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.9 | |||||
| 3-Year EBITDA Growth Rate | 21.5 | |||||
| 3-Year EPS without NRI Growth Rate | 92.6 | |||||
| 3-Year FCF Growth Rate | -8.8 | |||||
| 3-Year Book Growth Rate | 10.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 10.33 | |||||
| Future 3-5Y Total Revenue Growth Rate | -1.07 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.94 | |||||
| 9-Day RSI | 44.72 | |||||
| 14-Day RSI | 44.24 | |||||
| 6-1 Month Momentum % | 12.15 | |||||
| 12-1 Month Momentum % | 19.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.97 | |||||
| Quick Ratio | 0.57 | |||||
| Cash Ratio | 0.22 | |||||
| Days Inventory | 272.73 | |||||
| Days Sales Outstanding | 65.05 | |||||
| Days Payable | 125.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.04 | |||||
| Dividend Payout Ratio | 0.47 | |||||
| Forward Dividend Yield % | 4.09 | |||||
| 5-Year Yield-on-Cost % | 2.04 | |||||
| 3-Year Average Share Buyback Ratio | 0.1 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.11 | |||||
| Operating Margin % | 12.18 | |||||
| Net Margin % | 7.87 | |||||
| ROE % | 5.07 | |||||
| ROA % | 2.29 | |||||
| ROIC % | 3.22 | |||||
| ROC (Joel Greenblatt) % | 35.93 | |||||
| ROCE % | 5.24 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 22.1 | |||||
| Forward PE Ratio | 15.43 | |||||
| PE Ratio without NRI | 22.1 | |||||
| Price-to-Owner-Earnings | 9.12 | |||||
| PEG Ratio | 2.07 | |||||
| PS Ratio | 1.74 | |||||
| PB Ratio | 1.09 | |||||
| Price-to-Free-Cash-Flow | 20.31 | |||||
| Price-to-Operating-Cash-Flow | 7.19 | |||||
| EV-to-EBIT | 17.8 | |||||
| EV-to-Forward-EBIT | 15.08 | |||||
| EV-to-EBITDA | 8.5 | |||||
| EV-to-Forward-EBITDA | 10.17 | |||||
| EV-to-Revenue | 2.68 | |||||
| EV-to-Forward-Revenue | 2.85 | |||||
| EV-to-FCF | 31.45 | |||||
| Price-to-Projected-FCF | 0.73 | |||||
| Price-to-Median-PS-Value | 0.85 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.63 | |||||
| Earnings Yield (Greenblatt) % | 5.62 | |||||
| Forward Rate of Return (Yacktman) % | 21.75 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:TAK
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Takeda Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 29,535.642 | ||
| EPS (TTM) ($) | 0.743 | ||
| Beta | 0.3 | ||
| Volatility % | 18.3 | ||
| 14-Day RSI | 44.24 | ||
| 14-Day ATR ($) | 0.213624 | ||
| 20-Day SMA ($) | 16.363 | ||
| 12-1 Month Momentum % | 19.23 | ||
| 52-Week Range ($) | 12.28 - 17.15 | ||
| Shares Outstanding (Mil) | 3,121.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Takeda Pharmaceutical Co Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Takeda Pharmaceutical Co Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Takeda Pharmaceutical Co Ltd Frequently Asked Questions
What is Takeda Pharmaceutical Co Ltd(TAK)'s stock price today?
The current price of TAK is $16.12. The 52 week high of TAK is $17.15 and 52 week low is $12.28.
When is next earnings date of Takeda Pharmaceutical Co Ltd(TAK)?
The next earnings date of Takeda Pharmaceutical Co Ltd(TAK) is 2023-07-28 Est..
Does Takeda Pharmaceutical Co Ltd(TAK) pay dividends? If so, how much?
The Dividend Yield %  of Takeda Pharmaceutical Co Ltd(TAK) is 2.04% (As of Today), Highest Dividend Payout Ratio of Takeda Pharmaceutical Co Ltd(TAK) was 6.37. The lowest was 0.75. And the median was 1.23. The  Forward Dividend Yield % of Takeda Pharmaceutical Co Ltd(TAK) is 4.09%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers